Analysts’ Weekly Ratings Changes for Hinge Health (HNGE)

A number of firms have modified their ratings and price targets on shares of Hinge Health (NYSE: HNGE) recently:

• 11/7/2026 – Hinge Health was upgraded by Wall Street Zen from “hold” to “buy”.
• 11/6/2026 – Hinge Health was upgraded by Zacks Research from “hold” to “strong-buy”.
• 11/3/2026 – Hinge Health had its price target raised by Needham & Company LLC from $115.00 to $135.00. They now have a “buy” rating on the stock.
• 11/3/2026 – Hinge Health had its price target raised by Wells Fargo & Company from $103.00 to $132.00. They now have an “overweight” rating on the stock.
• 11/3/2026 – Hinge Health had its price target raised by Morgan Stanley from $117.00 to $131.00. They now have an “overweight” rating on the stock.
• 11/3/2026 – Hinge Health had its price target raised by Truist Financial from $112.00 to $145.00. They now have a “buy” rating on the stock.
• 11/3/2026 – Hinge Health had its price target raised by Royal Bank Of Canada from $110.00 to $135.00. They now have an “outperform” rating on the stock.
• 11/3/2026 – Hinge Health had its price target raised by Canaccord Genuity Group from $105.00 to $134.00. They now have a “buy” rating on the stock.
• 11/3/2026 – Hinge Health had its price target raised by Stifel Nicolaus from $130.00 to $135.00. They now have a “buy” rating on the stock.
• 10/26/2026 – Hinge Health had its price target raised by Stifel Nicolaus from $115.00 to $130.00. They now have a “buy” rating on the stock.
• 10/16/2026 – Hinge Health had its price target raised by KeyCorp from $125.00 to $140.00. They now have an “overweight” rating on the stock.
• 10/12/2026 – Hinge Health had its price target raised by Barclays from $100.00 to $110.00. They now have an “overweight” rating on the stock.
• 10/8/2026 – Hinge Health was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 9/30/2026 – Hinge Health had its price target raised by Needham & Company LLC from $97.00 to $115.00. They now have a “buy” rating on the stock.
• 9/29/2026 – Hinge Health is now covered by Bank of America. They set a “buy” rating and a $110.00 price target on the stock.
• 9/22/2026 – Hinge Health was upgraded by Weiss Ratings from “sell (d-)” to “hold (c)”.
• 9/22/2026 – Hinge Health had its price target raised by Robert W. Baird from $85.00 to $90.00. They now have a “neutral” rating on the stock.

Hinge Health Stock Performance

HNGE opened at $123.17 on Wednesday. The stock has a fifty day moving average of $102.11 and a 200-day moving average of $69.64. Hinge Health Inc. has a fifty-two week low of $30.08 and a fifty-two week high of $124.94. The company has a market capitalization of $9.94 billion, a P/E ratio of 62.84, a P/E/G ratio of 1.72 and a beta of 1.19.

Hinge Health (NYSE:HNGE) last released its quarterly earnings results on Monday, November 2nd. The company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.44. Hinge Health had a net margin of 21.02% and a return on equity of 73.91%. The company had revenue of $234.97 million during the quarter. During the same quarter in the previous year, the firm posted ($0.02) earnings per share. The firm’s quarterly revenue was up 52.4% on a year-over-year basis. On average, equities research analysts predict that Hinge Health Inc. will post 1.56 earnings per share for the current fiscal year.

Insider Activity

In other news, Chairman Gabriel Mecklenburg sold 250,000 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $88.97, for a total value of $22,242,500.00. Following the completion of the transaction, the chairman owned 250,000 shares of the company’s stock, valued at approximately $22,242,500. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President James Pursley sold 33,000 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $88.05, for a total transaction of $2,905,650.00. Following the completion of the sale, the president owned 706,235 shares in the company, valued at $62,183,991.75. This represents a 4.46% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,024,581 shares of company stock valued at $95,632,761 in the last three months. Company insiders own 18.92% of the company’s stock.

Hinge Health is a digital health company focused on musculoskeletal care, including support for people with back, joint and muscle pain. Its services are designed to help members manage conditions through personalized, technology-enabled care. The company’s offerings include app-based exercise therapy, education and behavioral support, along with access to clinical care teams. Hinge Health also uses wearable motion sensors in some programs to guide and track exercises. Founded in 2015, Hinge Health primarily provides its services through employers and health plans.